Professor Paul Ellis is a Consultant Medical Oncologist based in London, UK. He has a specialist interest in research into novel therapies in breast cancer management was heavily involved in chairing the UK Dept. of Health Advisory committee on the introduction of Herceptin into UK clinical practise, co-authoring the national guidelines of its use.
After attaining his Medical Degree from Otago University, New Zealand he then moved to London to complete his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital. It was here he submitted his MD thesis on the biological predictors of response to primary chemotherapy.
Professor Paul Ellis continues to take an active leadership role within the UK and European Clinical Trials community. He was the principal investigator and co-chair in the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been heavily involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including recently being Co-PI on the MARIANNE and KAMILLA trials.
It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.